Spyre Therapeutics Inc SYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
-
Spyre Therapeutics to Participate in Upcoming Investor Conference
-
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 2.58
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 30
- Website
- https://www.spyre.com
Comparables
Valuation
|
Metric
|
SYRE
|
VRDN
|
ARVN
|
|---|---|---|---|
Price/Earnings (Normalized) | 2.58 | — | — |
Price/Book Value | 6.43 | 4.70 | 2.82 |
Price/Sales | — | 4,598.90 | 11.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
SYRE
VRDN
ARVN
Financial Strength
|
Metric
|
SYRE
|
VRDN
|
ARVN
|
|---|---|---|---|
Quick Ratio | 19.26 | 15.54 | 3.57 |
Current Ratio | 19.70 | 15.82 | 3.62 |
Interest Coverage | — | −92.88 | — |
Quick Ratio
SYRE
VRDN
ARVN
Profitability
|
Metric
|
SYRE
|
VRDN
|
ARVN
|
|---|---|---|---|
Return on Assets (Normalized) | −42.01% | −34.35% | −22.33% |
Return on Equity (Normalized) | — | −64.16% | −47.53% |
Return on Invested Capital (Normalized) | −298.64% | −41.62% | −54.26% |
Return on Assets
SYRE
VRDN
ARVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rcddppxnr | Rwg | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pphvhrbdc | Ckpqn | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vszzqcy | Cgcjbl | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cvxkkjb | Sggxvp | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Fggkmdgxh | Dzv | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Xvxznqc | Lhlw | $28.3 Bil | |||
| Moderna Inc
MRNA
| Kwbptfnlv | Fhnv | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vdvzfqyq | Ltyth | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mdxhhxv | Fnbpphr | $13.3 Bil | |||
| Incyte Corp
INCY
| Txrbsqsqx | Ddfvpxy | $13.0 Bil |
United States